Published Papers & Misc - IKEDA SADAKATSU

41. Machiels Jean-Pascal H., Licitra Lisa F., Tao Yungan, Yen Chia-Jui, Rischin Danny, Waldron John, Burtness Barbara, Gregoire Vincent, Agarwala Sanjiv S., Yorio Jeffrey, Delord Jean-Pierre, Aksoy Sercan, Ikeda Sadakatsu, Hong Ruey-Long, Ge Joy Yang, Brown Holly M., Bidadi Behzad, Siu Lillian L.. Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study. JOURNAL OF CLINICAL ONCOLOGY. 2018.05; 36 (15):

42. Ikeda Sadakatsu, Lim Jordan S., Kurzrock Razelle. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics MOLECULAR CANCER THERAPEUTICS. 2018.05; 17 (5): 1114-1122. ( PubMed, DOI )

43. Kato Shumei, Kurasaki Kellie, Ikeda Sadakatsu, Kurzrock Razelle. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach ONCOLOGIST. 2018.02; 23 (2): 171-178. ( PubMed, DOI )

44. Riviere Paul, Fanta Paul T., Ikeda Sadakatsu, Baumgartner Joel, Heestand Gregory M., Kurzrock Razelle. The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA MOLECULAR CANCER THERAPEUTICS. 2018.01; 17 (1): 297-305. ( PubMed, DOI )

45. Machiels J-P., Yen C-J., Licitra L., Rischin D., Waldron J., Burtness B., Gregoire V., Tao Y. G., Yorio J., Aksoy S., Ikeda S., Hong R-L., Ge J. Y., Brown H., Bidadi B., Siu L.. Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) ANNALS OF ONCOLOGY. 2017.12; 28

46. Yen C-J., Machiels J-P., Licitra L., Rischin D., Waldron J., Burtness B., Gregoire V., Tao Y., Yorio J., Aksoy S., Ikeda S., Hong R-L., Ge J. Y., Brown H., Bidadi B., Siu L.. KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) ANNALS OF ONCOLOGY. 2017.11; 28

47. Machiels Jean-Pascal, Yen Chia-Jui, Licitra Lisa, Rischin Danny, Waldron John, Burtness Barbara, Gregoire Vincent, Agarwala Sanjiv, Tao Yun Gan, Yorio Jeffrey, Aksoy Sercan, Ikeda Sadakatsu, Hong Ruey-Long, Ge Joy Yang, Brown Holly, Bidadi Behzad, Siu Lillian. Phase 3 study of Pembrolizumab plus Chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC): KEYNOTE-412 JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2017.11; 5

48. Schwaederle Maria, Chattopadhyay Ranajoy, Kato Shumei, Fanta Paul T., Banks Kimberly C., Choi In Sil, Piccioni David E., Ikeda Sadakatsu, Talasaz AmirAli, Lanman Richard B., Bazhenova Lyudmila, Kurzrock Razelle. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing CANCER RESEARCH. 2017.10; 77 (19): 5419-5427. ( DOI )

49. Schwaederle Maria C, Patel Sandip P, Husain Hatim, Ikeda Megumi, Lanman Richard B, Banks Kimberly C, Talasaz AmirAli, Bazhenova Lyudmila, Kurzrock Razelle. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017.09; 23 (17): 5101-5111. ( PubMed, DOI )

50. Khemlina Galina, Ikeda Sadakatsu, Kurzrock Razelle. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies MOLECULAR CANCER. 2017.08; 16 149. ( PubMed, DOI )

51. Cohen Philip R., Kato Shumei, Goodman Aaron M., Ikeda Sadakatsu, Kurzrock Razelle. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2017.08; 18 (8): 1663. ( DOI )

52. Schwaederle Maria Clemence, Chattopadhyay Ranajoy, Kato Shumei, Fanta Paul T., Banks Kimberly, Piccioni David Eric, Ikeda Sadakatsu, Talasaz AmirAli, Lanman Richard B., Bazhenova Lyudmila, Kurzrock Razelle. Genomic alterations in 670 patients with diverse cancers analyzed by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 (15): ( DOI )

53. Patel Maulik, Ikeda Sadakatsu, Pilat Susan R., Kurzrock Razelle. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease JAMA DERMATOLOGY. 2017.05; 153 (5): 449-452. ( DOI )

54. Kato Shumei, Kurasaki Kellie, Ikeda Sadakatsu, Kurzrock Razelle. Rare tumor clinic: The UCSD Moores Cancer Center experience with a precision therapy approach. JOURNAL OF CLINICAL ONCOLOGY. 2017.05; 35 (15): ( DOI )

55. Ikeda Sadakatsu, Lim Jordan S., Kurzrock Razelle. Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma JOURNAL OF CLINICAL ONCOLOGY. 2017.02; 35 (4 S):

56. Millis Sherri Z., Ikeda Sadakatsu, Reddy Sandeep, Gatalica Zoran, Kurzrock Razelle. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors JAMA ONCOLOGY. 2016.12; 2 (12): 1565-1573. ( DOI )

57. Singh Alok R., Joshi Shweta, Burgoyne Adam M., Sicklick Jason K., Ikeda Sadakatsu, Kono Yuko, Garlich Joseph R., Morales Guillermo A., Durden Donald L.. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma MOLECULAR CANCER THERAPEUTICS. 2016.11; 15 (11): 2553-2562. ( DOI )

58. Schwaederle Maria, Husain Hatim, Fanta Paul T, Piccioni David E, Kesari Santosh, Schwab Richard B, Patel Sandip P, Harismendy Olivier, Ikeda Megumi, Parker Barbara A, Kurzrock Razelle. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016.11; 22 (22): 5497-5505. ( PubMed, DOI )

59. 池田 貞勝. プレシジョン・メディスン　ゲノム医療とその先へ 癌患者におけるゲノム配列分析の取り組み 日本癌学会総会記事. 2016.10; 75回 CS4-CS1. ( ichushi )

60. Ikeda Sadakatsu, Goodman Aaron M., Cohen Philip R., Jensen Taylor J., Ellison Christopher K., Frampton Garrett, Miller Vincent, Patel Sandip P., Kurzrock Razelle. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy NPJ GENOMIC MEDICINE. 2016.10; 1 16037. ( DOI )